Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); H.R. 2670-National Defense Authorization Act For Fiscal Year 2024; H.R. 1770/ S. 2477- Equitable Community Access to Pharmacists Services Act
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles; H.R. 1770/ S. 2477- Equitable Community Access to Pharmacists Services Act
Duration: January 14, 2019
to
present
General Issues: Medicare/Medicaid , Pharmacy , Taxation/Internal Revenue Code
Spending: about $840,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: House of Representatives, U.S. Senate, Executive Office of the President (EOP)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Sherry Widicus Legislative Director, Rep. Ron Kind
Legislative Assistant and Legislative Director, Rep. Kind
Brent Heberlee Legislative Asst and Director, Sen. Richard Bryan
Maria Tripplaar Staff Dir. & Chief Counsel, Comm on Veterans Affairs, House of Rep; Staff Dir., Comm on Veterans Affairs, House of Rep; Staff Dir. & Counsel, Subcommittee on Disability Assistance and Memorial Affairs, Comm. on Veterans' Affairs, House of Rep.
Timothy Jenkins n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Ballard Spahr LLP lobbied for Cencora, Inc. (Formerly AmerisourceBergen Corporation) , earning $50,000. The report was filed on April 22.
Original Filing: 301570691.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); H.R. 2670-National Defense Authorization Act For Fiscal Year 2024; H.R. 1770/ S. 2477- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles; H.R. 1770/ S. 2477- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Ballard Spahr LLP lobbied for Cencora, Inc. (Formerly AmerisourceBergen Corporation) , earning $50,000. The report was filed on Jan. 22.
Original Filing: 301536477.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); H.R. 2670-National Defense Authorization Act For Fiscal Year 2024; H.R. 1770/ S. 2477- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles; H.R. 1770/ S. 2477- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Ballard Spahr LLP lobbied for Cencora, Inc. (Formerly AmerisourceBergen Corporation) , earning $50,000. The report was filed on Oct. 20, 2023.
Original Filing: 301512804.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); H.R. 2670-National Defense Authorization Act For Fiscal Year 2024; H.R. 1770/ S. 2477- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles; H.R. 1770/ S. 2477- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $50,000. The report was filed on July 20, 2023.
Original Filing: 301486667.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); H.R. 2670-National Defense Authorization Act For Fiscal Year 2024; H.R. 7213- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles; H.R. 7213- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301463156.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); H.R. 799-National Defense Authorization Act For Fiscal Year 2023-amendment to establish a pilot program for pharmaceutical stockpiles; H.R. 7213- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles; H.R. 7213- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $50,000. The report was filed on Jan. 20, 2023.
Original Filing: 301440027.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); H.R. 799-National Defense Authorization Act For Fiscal Year 2023-amendment to establish a pilot program for pharmaceutical stockpiles; H.R. 7213- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles; H.R. 7213- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415040.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); H.R. 799-National Defense Authorization Act For Fiscal Year 2023-amendment to establish a pilot program for pharmaceutical stockpiles; H.R. 7213- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles; H.R. 7213- Equitable Community Access to Pharmacists Services Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301392403.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); H.R. 799-National Defense Authorization Act For Fiscal Year 2023-amendment to establish a pilot program for pharmaceutical stockpiles
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $40,000. The report was filed on April 20, 2022.
Original Filing: 301368589.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $40,000. The report was filed on Jan. 20, 2022.
Original Filing: 301336985.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution; H.R. 5376- Build Back Better Act; H.R 2870 Essential Medicines Strategic Stockpile Act of 2021-provisions related to medical supply chains and strategic stock piles
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301311540.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $40,000. The report was filed on July 20, 2021.
Original Filing: 301291039.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $40,000. The report was filed on April 20, 2021.
Original Filing: 301263019.xml
Lobbying Issues
Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); Proposals relating to the Strategic National Stock Pile; COVID-19 vaccine distribution
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $30,000. The report was filed on Jan. 20, 2021.
Original Filing: 301241920.xml
Lobbying Issues
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $30,000. The report was filed on Oct. 20, 2020.
Original Filing: 301221203.xml
Lobbying Issues
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $30,000. The report was filed on July 20, 2020.
Original Filing: 301199152.xml
Lobbying Issues
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $30,000. The report was filed on April 20, 2020.
Original Filing: 301175883.xml
Lobbying Issues
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $30,000. The report was filed on Jan. 21, 2020.
Original Filing: 301126760.xml
Lobbying Issues
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $30,000. The report was filed on Oct. 21, 2019.
Original Filing: 301075170.xml
Lobbying Issues
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection. International Pricing Index Model.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress); H.R. 3 Lower Drug Costs Now Act of 2019
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $30,000. The report was filed on July 22, 2019.
Original Filing: 301055361.xml
Lobbying Issues
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection. International Pricing Index Model.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Ballard Spahr LLP lobbied for AmerisourceBergen Corporation , earning $20,000. The report was filed on April 22, 2019.
Original Filing: 301036357.xml
Lobbying Issues
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection. International Pricing Index Model.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
Ballard Spahr LLP filed a lobbying registration on March 4, 2019 to represent AmerisourceBergen Corporation, effective Jan. 14, 2019.
Original Filing: 301021056.xml
Issue(s) they said they’d lobby about: Medicare reimbursement, drug pricing, prescription drug abuse, and general tax provisions .
1st Quarter, 2019
Ballard Spahr LLP filed a lobbying registration on Feb. 13, 2019 to represent AmerisourceBergen Corporation, effective Jan. 14, 2019.
Original Filing: 301020303.xml
Issue(s) they said they’d lobby about: Medicare reimbursement, drug pricing, prescription drug abuse, and general tax provisions. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...